drugset / Trial / NCT04397276
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.
Timeline
- Start
- 2020-07-10
- Primary completion
- 2025-09-16
- Completion
- 2025-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-70218902 | Other / unclassified | — | — |